Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
Total Valuation
Day One Biopharmaceuticals has a market cap or net worth of $1.06B. The enterprise value is $280.15M.
Market Cap$1.06B
Enterprise Value$280.15M
Share Statistics
Day One Biopharmaceuticals has 102,675,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding102,675,500
Owned by Insiders4.19%
Owned by Institutions28.81%
Financial Efficiency
Day One Biopharmaceuticals’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -39.21%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.16
Return on Invested Capital (ROIC)-39.21%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee724.65K
Profits Per Employee-527.60K
Employee Count181
Asset Turnover0.23
Inventory Turnover1.59
Valuation Ratios
The current PE Ratio of Day One Biopharmaceuticals is ―. Day One Biopharmaceuticals’s PEG ratio is 0.22.
PE Ratio―
PS Ratio9.04
PB Ratio2.36
Price to Fair Value2.36
Price to FCF-14.78
Price to Operating Cash Flow-8.41
PEG Ratio0.22
Income Statement
In the last 12 months, Day One Biopharmaceuticals had revenue of 131.16M and earned -95.50M in profits. Earnings per share was -1.02.
Revenue131.16M
Gross Profit125.88M
Operating Income-217.27M
Pretax Income-88.35M
Net Income-95.50M
EBITDA-86.32M
Earnings Per Share (EPS)-1.02
Cash Flow
In the last 12 months, operating cash flow was -119.62M and capital expenditures -1.74M, giving a free cash flow of -121.36M billion.
Operating Cash Flow-119.62M
Free Cash Flow-121.36M
Free Cash Flow per Share-1.18
Dividends & Yields
Day One Biopharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.23
52-Week Price Change-33.88%
50-Day Moving Average7.60
200-Day Moving Average7.69
Relative Strength Index (RSI)55.42
Average Volume (3m)2.23M
Important Dates
Day One Biopharmaceuticals upcoming earnings date is Mar 9, 2026, After Close (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 9, 2026
Ex-Dividend Date―
Financial Position
Day One Biopharmaceuticals as a current ratio of 7.66, with Debt / Equity ratio of 0.64%
Current Ratio7.66
Quick Ratio7.61
Debt to Market Cap<0.01
Net Debt to EBITDA1.42
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Day One Biopharmaceuticals has paid 7.14M in taxes.
Income Tax7.14M
Effective Tax Rate0.08
Enterprise Valuation
Day One Biopharmaceuticals EV to EBITDA ratio is -12.32, with an EV/FCF ratio of -13.25.
EV to Sales8.11
EV to EBITDA-12.32
EV to Free Cash Flow-13.25
EV to Operating Cash Flow-13.62
Balance Sheet
Day One Biopharmaceuticals has $451.58M in cash and marketable securities with $2.89M in debt, giving a net cash position of $448.69M billion.
Cash & Marketable Securities$451.58M
Total Debt$2.89M
Net Cash$448.69M
Net Cash Per Share$4.37
Tangible Book Value Per Share$5.20
Margins
Gross margin is 89.44%, with operating margin of -165.65%, and net profit margin of -72.81%.
Gross Margin89.44%
Operating Margin-165.65%
Pretax Margin-67.36%
Net Profit Margin-72.81%
EBITDA Margin-65.81%
EBIT Margin-67.36%
Analyst Forecast
The average price target for Day One Biopharmaceuticals is $23.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.57
Price Target Upside166.33% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast31.11%
EPS Growth Forecast-46.75%